RxDoctor Payments Data

Denisea Mount

Family · Centerville, OHNPI 1902423726

Payments from drug & device makers

$4,913in general payments, 2019–2025

Across 250 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Grifols USA, LLC$1K
  • AstraZeneca$1K
  • GSK$597
  • Mylan Specialty L.p.$498
  • Takeda Pharmaceuticals U.S.A., Inc.$340
  • Sanofi$198
  • plus $871 from 20 others

What the payments were for

  • Food & beverage$4,913100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,913 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$22,205
Medicare patients
139
Services billed
464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter72$96,577
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$26,870
Combivent RespimatIpratropium/Albuterol Sulfate14$21,806
Breo ElliptaFluticasone/Vilanterol32$20,623
Spiriva RespimatTiotropium Bromide15$14,949
Clarithromycin114$13,136
Azithromycin424$10,527
Albuterol Sulfate HfaAlbuterol Sulfate254$9,357
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate39$7,936
Fluticasone-SalmeterolFluticasone Propion/Salmeterol31$6,966
Doxycycline Hyclate255$6,569
Minocycline Hcl71$5,545
SymbicortBudesonide/Formoterol Fumarate16$3,762
Wixela InhubFluticasone Propion/Salmeterol20$3,029
Prednisone281$1,651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$597$117,199104 claims
Boehringer IngelheimCombivent Respimat, Spiriva Respimat$36$36,75529 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,129$30,63340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.

Other family in Centerville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →